The study by Chen et al. [52] demonstrated a histone deacetylation-independent mechanism whereby HDAC inhibitors sensitized prostate cancer cell lines to DNA-damaging chemotherapeutic drugs, bleomycin, doxorubicin and etoposide. The gene discussed is HDAC9; the disease is prostate cancer.